LIGAND PHARMACEUTICALS (LGND)
LIGAND PHARMACEUTICALS Revenue Growth: 44.66%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LGND Revenue Growth Rankings
| Overall | 90th percentile | 400 of 4364 |
| Sector | 83rd percentile | 74 of 456 in Healthcare |
| Industry | 54th percentile | 5 of 11 in Drugs - Generic |
LGND Revenue Growth Range, Past 5 Years
| Minimum | -71.81% | Dec 2010 |
| Maximum | 1974% | Mar 2008 |
| Average | 148.9% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these LGND related companies
LGND News
Ligand Pharmaceuticals (LGND) Says Glaxo (GSK) Submits Regulatory Apps for Promacta/Revolade
May 30, 10:17AM Street Insider
May 30, 10:17AM Street Insider
$LGND may extend last week's move to 14.50, we got buy signal 5/24 which may last 14 days. Target price 14.50
about 3 days ago by woowtrading
about 3 days ago by woowtrading
$LGND Insider Sale: $2.3M of stock sold by David Knott on May 24, 2012 http://stks.co/3zbT
about 5 days ago by MarketBrief
about 5 days ago by MarketBrief
$LGND Ligand partner abstracts posted for ASCO 2012 for Promacta, Kyprolis, CUDC-101 and ME-143 http://stks.co/3sZF
about 13 days ago by Ligand_LGND
about 13 days ago by Ligand_LGND
$LGND presents at Merril Lynch Healthcare on Thursday, Jeffries on June 4, and has a panel date on 6/20.
about 15 days ago by britepathos
about 15 days ago by britepathos
CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4
May 14, 12:21PM Business Wire
May 14, 12:21PM Business Wire
Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17
May 07, 3:15PM Business Wire
May 07, 3:15PM Business Wire
$LGND to report earnings results on May 2nd at 4:30 pm ET. Webcast/cc at: http://stks.co/3Z5U
about 32 days ago by abubnic
about 32 days ago by abubnic
$LGND This week's top stories in technology 4/23-4/27 http://stks.co/3Z4k
about 32 days ago by ericjones12398
about 32 days ago by ericjones12398
$LGND Ligand partner Merck posted May 2012 as start date for P3 Dinaciclib evaluation study on http://stks.co/3YYR http://stks.co/3YYS
about 33 days ago by Ligand_LGND
about 33 days ago by Ligand_LGND
$LGND Ligand Captisol partner Onyx announced FDA Advisory Committee, ODAC, to review NDA for Carfilzomib on June 20 http://stks.co/3WrZ
about 34 days ago by Ligand_LGND
about 34 days ago by Ligand_LGND
$LGND Ligand partner GSK reported Promacta sales of $43M in Q1, more than doubling compared to $19 million in Q1 2011, http://stks.co/3VQE
about 35 days ago by Ligand_LGND
about 35 days ago by Ligand_LGND
$LGND Clinical study of Ligand’s LGD-4033 (SARM) program published in most recent Journal of Gerontology http://stks.co/3Edn
about 55 days ago by Ligand_LGND
about 55 days ago by Ligand_LGND
@ChartSwingTrade I would say $HSFT,$LGND, $GMAN, $KIRK look great to me even before scanning for tomorrow
about 79 days ago by ivan_bg
about 79 days ago by ivan_bg
$LGND over 16 looks like a decent swing trade to ~20. Beware It's lightly traded.
about 80 days ago by Contrarius
about 80 days ago by Contrarius
$LGND Ligand partner Onyx completes ASPIRE P3 enrollment for Carfilzomib; completion of NDA review expected by July 27 http://stks.co/2Zk8
about 93 days ago by Ligand_LGND
about 93 days ago by Ligand_LGND
Ligand to Present at the Citi Global Health Care Conference on February 28th
Feb 21, 12:30PM Business Wire
Feb 21, 12:30PM Business Wire
Ligand (LGND) Licenses DARA to Retrophin; May Get Up to $75M in Milestone Payments
Feb 21, 8:51AM Street Insider
Feb 21, 8:51AM Street Insider
$LGND is at $14.700 and is forming a base right now. When $LGND breaks above $15.910 on at least 174,027 share volume day,buy $LGND.
about 110 days ago by sundeeptrade
about 110 days ago by sundeeptrade
Ligand to Present at the BIO CEO and Investor Conference on February 13
Feb 09, 12:45PM Business Wire
Feb 09, 12:45PM Business Wire
Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
Feb 07, 4:49PM Street Insider
Feb 07, 4:49PM Street Insider
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Feb 07, 8:00AM Business Wire
Feb 07, 8:00AM Business Wire
Ligand Pharma (LGND) Completes PG-Free Melphalan Phase II, Issues Update
Feb 02, 6:47AM Street Insider
Feb 02, 6:47AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LGND | 12.81 | +0.15 | +1.18% | 249.15M |
| LGL | 6.91 | +0.05 | +0.73% | 17.83M |
| LGI | 13.60 | +0.10 | +0.74% | |
| LGF | 12.75 | -0.16 | -1.24% | 1.774B |
| LGCY | 25.55 | -0.53 | -2.03% | 1.250B |
| LG | 38.29 | +0.10 | +0.26% | 858.89M |
| LFUS | 57.82 | -0.95 | -1.62% | 1.270B |
| LFL | 23.77 | -0.54 | -2.22% | 8.273B |
| LFC | 34.95 | -1.19 | -3.29% | 17.93B |
| LF | 10.37 | -0.07 | -0.67% | 577.96M |